Herbal formula
Sinupret (BNO 1016)
Also known as Sinupret extract, Sinupret eXtract, BNO 1016, Sinupret forte, Sinupret Saft, Sinupret Adult Strength, BNO 101, five-herb sinus formula
A German five-herb sinus extract that eased acute viral sinusitis modestly faster than placebo in two manufacturer-funded trials.
Main use: Acute viral sinusitis
Promising clinical evidence
5 ingredients
Updated October 10, 2026
Key points
-
01
Five herbs in a fixed 1:3:3:3:3 ratio
Gentian root, cowslip flower, dock or sorrel herb, elder flower, and vervain herb. The version tested in modern trials is BNO 1016, a 160 mg extract tablet.
-
02
A modest benefit in acute viral sinusitis
In 589 pooled adults, symptom scores reached 2.47 with BNO 1016 and 3.63 with placebo after 14 days; about ten people needed treatment for one extra recovery.
-
03
The key trials were funded by the manufacturer
Bionorica sponsored the main acute and chronic sinusitis trials. EPOS 2020 still lists BNO 1016 tablets among herbal medicines with a significant effect on symptoms.
-
04
Not shown to help chronic sinusitis
In 929 adults treated for 12 weeks, BNO 1016 did not beat placebo on its main measure; only subgroups picked after the fact improved.
-
05
Stomach upset and allergy are the main risks
Avoid it with a stomach ulcer, and the extract label advises against it in pregnancy, breastfeeding, and under 12. Eye swelling or severe pain needs a doctor.
Sinupret is a German herbal medicine for sinus inflammation made by Bionorica SE of Neumarkt, Bavaria. Every version combines the same five plants, gentian root, cowslip (primula) flower, dock or sorrel herb, elder flower, and vervain herb, in a fixed ratio of 1:3:3:3:3. The best-studied version is Sinupret extract (sold in Germany as Sinupret eXtract), a green coated tablet containing 160 mg of a concentrated dry extract known in research papers by its code, BNO 1016. Older forms, often grouped in the literature as BNO 101, include Sinupret forte tablets made from the powdered herbs themselves and a syrup for children, Sinupret Saft. In Germany the extract tablet is a licensed, pharmacy-only medicine for acute, uncomplicated sinusitis in adults and adolescents from age 12. In the United States, Bionorica sells Sinupret Adult Strength tablets and a Kids Syrup as herbal supplements, and the adult tablets list different amounts of the herbs from either German tablet.
Sinupret is one of the oldest branded herbal combinations still on sale. Josef Popp founded Bionorica in Nuremberg in 1933, selling natural remedies and almost 400 kinds of tea, and by the time Melzer and colleagues reviewed the formula in 2006 it had been widely used in Germany for respiratory infections for about 70 years. The early research tested the older forms, usually as an add-on to antibiotics. The trial that later supported approval in Sweden, by Neubauer and März (1994), gave 160 young men with mainly acute sinusitis Sinupret or placebo on top of an antibiotic and a decongestant. Bionorica’s company history records that Sinupret and Sinupret forte were newly registered in Germany in 1997. The concentrated extract came much later: Germany authorized Sinupret extract in August 2012, it was launched that autumn, and the company says it reached ten more countries in 2014.
How Sinupret might work is not settled. Swissmedic’s product information states that there are no human pharmacodynamic studies of the extract. In animal and laboratory studies of the drops, the product loosened mucus in rabbits, reduced paw swelling in rats, slowed rhinovirus, adenovirus, and respiratory syncytial virus in cell cultures, and lowered deaths in mice infected with parainfluenza virus, but none of this shows what happens in a human sinus. Sweden’s Medical Products Agency concluded that no single substance can be credited with the effect, which probably depends on several compounds and mechanisms. This page covers what is in each version, what the trials of the combination found, how it is taken, and when it should not be used. The results belong to the product, not to gentian, cowslip, dock, elder, or vervain on their own, and they apply most clearly to the BNO 1016 tablet at the trial dose. Nothing here is medical advice.
See also
Herbs for Colds, Flu and Immunity02 The blend
What’s in it
Ingredients in label order. Results from trials of this formula belong to the combination, not to any single herb in it.
-
Gentian · Root
1 of 13 parts of the herb mixture
Gentiana lutea
Gentiana lutea, the classic European bitter, is the smallest share of the blend. Sinupret forte tablets contain 12 mg of the powdered root. What gentian adds to the sinus effect cannot be separated from the other herbs.
Read the gentian monograph →
-
Cowslip (primula) · Flower
3 of 13 parts of the herb mixture
Primula veris
Primula veris flowers (Swedish documents also allow oxlip, P. elatior). EMA accepts primula flower as a traditional expectorant for cough with a cold but left the Sinupret trials out of its assessment. The flowers can rarely cause allergy.
Read the cowslip monograph →
-
Sorrel (curled dock) · Herb (leaves and upper stems)
3 of 13 parts of the herb mixture
Rumex crispus
The Swiss label for Sinupret extract names curled dock, Rumex crispus; the German label says only dock herb. Sinupret forte and the syrup list garden sorrel (R. acetosa), and the US tablets list six Rumex species.
Read the yellow dock monograph →
-
Elder flower · Flower
3 of 13 parts of the herb mixture
Sambucus nigra
Sambucus nigra flowers, not the berries; our elderberry monograph covers both parts. On its own, EMA accepts elderflower as a traditional remedy for the early symptoms of a common cold, based on long use.
Read the elderberry monograph →
-
Vervain (verbena) · Herb (leaves and upper stems)
3 of 13 parts of the herb mixture
Verbena officinalis
Verbena officinalis, not lemon verbena. The European Pharmacopoeia sets its quality standard. As with each of the five herbs, its share of the product’s effect cannot be separated out.
Read the vervain monograph →
03 Evidence
What the research shows
Our rating for acute viral sinusitis, based on trials of this combination.
The key trial is ARhiSi-2. Jund and colleagues (Rhinology 2012) randomized adults whose acute viral rhinosinusitis had begun no more than three days earlier, with mild to moderate facial pain and a major symptom score (MSS) of 8 to 12 out of 15, to one BNO 1016 tablet three times a day or placebo for 15 days. The MSS adds up a doctor’s ratings of five symptoms: runny nose, postnasal drip, blocked nose, headache, and facial pain or pressure. According to the German prescribing information, 386 patients were randomized, 194 to the extract and 192 to placebo. At the final visit the MSS averaged 2.38 points with BNO 1016 and 3.41 with placebo (p = 0.008), a gap that just reached the one-point difference set in advance as clinically relevant; blocked nose on its own did not differ significantly. Symptoms eased about two days sooner, eight people needed treatment for one extra person to be healed, quality of life improved more, and no serious adverse events occurred. Bionorica sponsored the trial.
Jund and colleagues (Acta Oto-Laryngologica 2015) then pooled ARhiSi-2 with an earlier dose-finding trial, ARhiSi-1; both ran in 2009 and 2010 at 37 German centers. Using only patients who met the ARhiSi-2 entry rules and took 480 mg a day or placebo, the analysis included 589 adults, 294 on BNO 1016 and 295 on placebo. The average MSS started at about 10 points in both groups and fell to 2.47 with the extract and 3.63 with placebo by day 14, a difference of 1.16 points that the authors equated to recovery almost three days faster. At day 14, 93.2% versus 85.1% were rated healed or improved, the number needed to treat was 10, and patient-rated quality of life also favored the extract (p = 0.0015). Most people improved a great deal on placebo, as expected in a condition that usually clears on its own. Bionorica funded the work; one author was a company employee, two were scientific consultants to it, and another ran the contract research organization that conducted the trials.
Reviews point the same way, with caveats about quality and independence. Melzer and colleagues (Forschende Komplementärmedizin 2006) found 22 studies of the older powdered-herb product, BNO 101; in two placebo-controlled trials with 319 patients in which it was added to antibiotics, 61.1% on Sinupret rated themselves cured after two weeks against 34.5% on placebo, but participants were mostly young men. Koch and colleagues (Forschende Komplementärmedizin 2016) judged that BNO 1016 and BNO 101 “might be helpful” in acute sinusitis but stressed the small number of trials and their mixed quality, and a 2025 systematic review in Rhinology by Choulakis and colleagues, covering 33 studies of 11 herbal preparations, concluded that BNO 1016 presents significant evidence for acute rhinosinusitis. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) rates the evidence at level Ib and says BNO 1016 tablets, Pelargonium sidoides drops, and Myrtol capsules have a significant impact on symptoms of acute post-viral rhinosinusitis without significant adverse events. It makes a similar statement for the common cold, naming BNO 1016 with cineole and Andrographis, while noting that a formal systematic review is missing.
Not every trial was positive. In CRS-02, the largest Sinupret study, Palm and colleagues (Rhinology 2017) randomized 929 adults with chronic rhinosinusitis to one of two doses of BNO 1016 or placebo for 12 weeks. The extract did not beat placebo on the primary endpoint, the MSS at weeks 8 and 12. Benefits appeared only in subgroups analyzed after the fact, such as people with more severe, longer-lasting disease; such findings can suggest a new trial but cannot prove an effect. Bionorica sponsored this trial too, and EPOS 2020 concluded that it cannot advise on herbal medicine for chronic rhinosinusitis. In children the evidence is open-label: Popovych and colleagues (American Journal of Otolaryngology 2020) randomized 292 children aged 6 to 11 to the syrup, coded BNO 1012, plus standard care or standard care alone for 10 days and reported greater early reductions in runny nose, congestion, and postnasal drip and fewer antibiotic prescriptions. A 2025 review by Kamin and colleagues, funded by the maker of a rival pelargonium extract, rated the five-herb syrup a possible add-on treatment for children, with a low grade of recommendation (IIC).
Regulators treat Sinupret as a national medicine rather than an EU-wide one. No European Union herbal monograph covers the combination: the European Medicines Agency (EMA) summary on primula flower says combinations are not covered, and its 2012 assessment report set aside the Sinupret trials because the flower’s share of the effect cannot be estimated. Germany authorized Sinupret extract in 2012 as a pharmacy-only medicine, Switzerland authorizes it for adults only, and Sweden approved the powdered-herb tablets in 2012 as well-established herbal medicines on the strength of the 1994 add-on trial and more than ten years of use in the EU. In the United States the products are sold as herbal supplements, not as approved drugs. Much remains unknown: which compounds are active, whether the benefit holds up in trials run independently of the manufacturer, and how well the syrup works in young children. The results also cannot be borrowed from, or lent to, the single herbs. EMA could not estimate the flower’s contribution, the Swedish agency could not credit any single substance, and the powdered tablets and syrup differ in dose and form from the tested extract.
04 In practice
How it is taken
Sinupret comes in several forms that are not interchangeable. Sinupret extract (BNO 1016) is a coated tablet containing 160 mg of dry extract, made with ethanol from the five-herb mixture at a drug-to-extract ratio of 3–6:1. Sinupret forte tablets contain the powdered herbs instead: 12 mg of gentian root and 36 mg each of vervain herb, garden sorrel herb, elder flower, and cowslip flower with calyx; Germany licenses them for acute and chronic sinus inflammation. Sinupret Saft is a syrup made from a water-and-alcohol extract of the same mixture and contains 450 mg of alcohol in each 7 ml adult dose. In the United States, Sinupret Adult Strength tablets list 30 mg each of primula flower, sorrel, elder flower, and vervain and 10 mg of gentian root, amounts that match neither German tablet. If you want the product tested in the modern placebo-controlled trials, look for a label that names BNO 1016 or states 160 mg of dry extract per tablet.
In the acute sinusitis trials, adults took one 160 mg BNO 1016 tablet three times a day, 480 mg in total, for 15 days. The German label gives the same dose for adults and adolescents from age 12: one tablet in the morning, at midday, and in the evening, swallowed whole with some liquid, after meals for people with a sensitive stomach, for 7 to 14 days unless a doctor advises otherwise. Sinupret forte is also taken as one tablet three times a day from age 12. For Sinupret Saft, the German prescribing information gives 2.1 ml three times a day for children aged 2 to 5, 3.5 ml for ages 6 to 11, and 7 ml for adolescents and adults, again for 7 to 14 days; it is not for children under 2. The chronic sinusitis trial used 12 weeks of treatment without a convincing benefit, so there is no evidence-based case for long courses.
The labels say to see a doctor if symptoms last longer than 7 to 14 days, get worse, or keep coming back. EPOS 2020 suggests that a clinician consider bacterial sinusitis when at least three of these are present: fever above 38 °C (100.4 °F), a second worsening after initial improvement, symptoms on one side, severe pain, or raised blood markers of inflammation. Stop the product at the first sign of an allergic reaction and do not take it again. When choosing a form, it helps to know which evidence stands behind it: only the BNO 1016 extract was tested in the modern placebo-controlled trials in adults, the powdered tablets rest mainly on add-on trials from the 1990s, and the children’s syrup rests on open-label studies. Other five-herb blends sold under different names cannot be assumed to behave the same way. A pharmacist can check the label against your medicines, allergies, and health conditions.
05 Caution
Before you use Sinupret (BNO 1016)
Sinupret extract is usually well tolerated, but it does cause side effects. The German and Swiss prescribing information list stomach and gut complaints, such as nausea, bloating, diarrhea, dry mouth, and stomach pain, as common (up to 1 in 10 people), and dizziness and skin allergy as uncommon (up to 1 in 100). Allergic reactions can be mild, with rash, redness, or itching of the skin or eyes, or severe, with swelling of the lips, tongue, throat, or face and difficulty breathing. In the acute trials, adverse events affected 8.7% of people on BNO 1016 versus 4.7% on placebo in ARhiSi-1 and 9.8% versus 14.1% in ARhiSi-2, mostly mild to moderate, with no serious events. Sweden’s Medical Products Agency notes isolated reports of serious skin reactions, including erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis, in people treated with Sinupret. EMA’s primula flower assessment adds that the flowers may contain allergenic quinones, so people known to react to primroses should be cautious.
Do not take Sinupret extract if you are allergic to any of its ingredients or have, or have had, a stomach or duodenal ulcer, and take extra care, ideally after meals, if you have gastritis or a sensitive stomach. Because the tablets contain sucrose and glucose, people with hereditary fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency should not use them. Age limits differ by country and form: Germany allows the extract and forte tablets from age 12 and the syrup from age 2, while Switzerland does not allow the extract under 18 because its use in younger people has not been adequately studied. In pregnancy, the German and Swiss extract labels advise avoiding it as a precaution, and both say it should not be used while breastfeeding because it is unknown whether its constituents pass into milk. The syrup’s label is less strict, citing a retrospective analysis of 762 pregnancies exposed to Sinupret drops or powder that found no sign of harm to the baby, but the syrup contains alcohol. There are no dosing data for people with reduced kidney or liver function.
No systematic interaction studies have been done with Sinupret extract, so its German label says that a stronger or weaker effect of other medicines cannot be ruled out and that combining it with medicines that have a narrow safety margin should be decided case by case. The forte and syrup labels state that no interactions are known but that none have been studied. Among the ingredients, EMA’s monographs on gentian root, primula flower, and elder flower all report no interactions, which reflects an absence of reports rather than proof of safety. Vervain and dock herb have not been assessed for interactions in the sources reviewed for this page, and the Swedish agency notes that no European Pharmacopoeia monograph exists for the dock herb, which Bionorica controls with its own specification. The syrup’s alcohol matters for anyone avoiding alcohol or taking medicines that should not be combined with it. If you take regular prescription medicines, ask a pharmacist before adding Sinupret, and mention it to any doctor treating you.
Sinusitis usually follows a cold and clears on its own, but some symptoms need medical care instead of a herbal remedy. The Sinupret labels list nosebleeds, fever, severe pain, pus-like nasal discharge, vision problems, a lopsided face or eyes, and numbness in the face as warning signs of severe sinusitis that need a doctor’s assessment. EPOS 2020 calls for immediate referral for swelling or redness around the eye, a displaced eyeball, double vision, difficulty moving the eye, reduced vision, severe headache, swelling over the forehead, signs of sepsis or meningitis, or other neurological signs. Seek care, too, if symptoms last more than 10 days or get worse after five days, or if they keep coming back. Sinupret should never be used to put off care when these signs appear, and it does not replace antibiotics when a clinician judges them necessary.
06 Questions
Frequently Asked Questions
Five herbs in a 1:3:3:3:3 ratio: gentian root, cowslip (primula) flower, dock or sorrel herb, elder flower, and vervain herb. The Swiss label for Sinupret extract names the dock as curled dock, covered in our yellow dock monograph, while German forte and syrup labels list garden sorrel. Elder flower is covered in our elderberry monograph. The extract tablet (BNO 1016) holds 160 mg of concentrated dry extract; Sinupret forte contains the powdered herbs.
For acute viral sinusitis after a cold, it seems to help a little. In two pooled placebo-controlled trials with 589 adults, symptom scores on a 15-point scale fell from about 10 to 2.47 with BNO 1016 and to 3.63 with placebo after 14 days, roughly ten people needed treatment for one extra recovery, and symptoms eased about two to three days sooner. Bionorica funded both trials. EPOS 2020 lists BNO 1016 tablets among herbal medicines with a significant effect on symptoms of acute post-viral sinusitis.
No. Sinupret extract contains 160 mg of a concentrated dry extract (BNO 1016) and is the version tested in the modern placebo-controlled trials. Sinupret forte contains the powdered herbs, 12 mg of gentian root and 36 mg of each of the other four, and its evidence comes mainly from older trials in which it was added to antibiotics. The US Sinupret Adult Strength tablets list yet another set of amounts and are sold as herbal supplements.
Only certain forms and ages. In Germany the extract and forte tablets are for ages 12 and up, and Sinupret Saft syrup is licensed from age 2, at 2.1 ml three times a day for ages 2 to 5 and 3.5 ml for ages 6 to 11; it contains some alcohol. Switzerland does not allow the extract under 18. Studies in children are open-label, without a placebo group, so the evidence is weaker than in adults. A child with fever, swelling around the eye, or severe pain needs a doctor.
The German and Swiss labels for Sinupret extract advise avoiding it in pregnancy as a precaution and say it should not be used while breastfeeding, because no one knows whether its constituents reach breast milk. A retrospective German study of 762 pregnancies exposed to older Sinupret forms found no sign of birth defects, and the syrup label allows use in pregnancy when clinically needed, but that is not the same as proven safety. Ask your doctor or midwife first.
Not convincingly. In the largest trial, 929 adults with chronic rhinosinusitis took BNO 1016 or placebo for 12 weeks, and the extract did not beat placebo on the main measure. A benefit appeared only in subgroups chosen after the results were in, which is not reliable proof. EPOS 2020 concluded that it cannot advise on herbal medicine for chronic rhinosinusitis. Sinus symptoms lasting more than 12 weeks deserve an assessment by a doctor or ear, nose, and throat specialist.
It is not an antibiotic. The modern trials enrolled people with viral sinusitis, which antibiotics do not help, and EPOS 2020 advises avoiding antibiotics for viral and post-viral sinusitis. When bacterial sinusitis is likely, for example with fever above 38 °C (100.4 °F), a second worsening, severe one-sided pain, or raised inflammation markers, a clinician may decide antibiotics are needed, and Sinupret should not delay that decision. Swelling around the eye, vision changes, or a severe headache need urgent care.
EPOS 2020 lists BNO 1016 tablets alongside pelargonium drops and myrtol capsules as herbal medicines with a significant effect on acute post-viral sinusitis. No randomized trial comparing them directly was found for this page. Each has its own funding history and safety profile; see our page on Myrtol (ELOM-080) and our eucalyptus monograph for cineole. None should replace a medical assessment when warning signs appear.
07 References
Sources
These references support the claims on this page. They are not an endorsement of any product. Each ingredient’s monograph carries its own full source list.
-
Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis
Rhinology (PubMed 23193534), 2012
Jund et al., ARhiSi-2: BNO 1016 versus placebo for 15 days in acute viral rhinosinusitis; symptom relief two days earlier; number needed to treat 8; no serious adverse events; ClinicalTrials.gov NCT01146860, sponsored by Bionorica.
-
Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis
Acta Oto-Laryngologica (PubMed 25496178), 2015
Jund et al.: pooled ARhiSi-1 and ARhiSi-2, 589 adults, 3 × 160 mg for 15 days; MSS from about 10 to 2.47 versus 3.63; 93.2% versus 85.1% responders; number needed to treat 10; adverse event rates by trial; Bionorica funding and author ties.
-
Assessment of efficacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis
Rhinology (PubMed 28214913), 2017
Palm et al., CRS-02: 929 adults with chronic rhinosinusitis, two doses or placebo for 12 weeks; primary endpoint not met; benefits only in post hoc subgroups; registered as NCT01706484 with Bionorica as sponsor.
-
Executive summary of EPOS 2020 including integrated care pathways
Rhinology (PubMed 32226949), 2020
Level Ib: BNO 1016 tablets, Pelargonium sidoides, and Myrtol have significant impact on acute post-viral rhinosinusitis symptoms; no advice possible on herbal medicine in chronic rhinosinusitis; bacterial sinusitis criteria and alarm symptoms.
-
Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis
Forschende Komplementärmedizin (PubMed 16645287), 2006
Melzer et al.: 22 studies of the powdered-herb product, about 70 years of use in Germany; two add-on trials with antibiotics, 61.1% versus 34.5% cured; mostly young adult men; adverse events similar to placebo.
-
A Systematic Review of Phytotherapy for Acute Rhinosinusitis
Forschende Komplementärmedizin (PubMed 27404100), 2016
Koch et al.: seven trials of six herbal products; BNO 1016 and BNO 101 might be helpful; few trials and heterogeneous risk of bias.
-
Traditional herbal medicine in the treatment of acute and chronic rhinosinusitis: a systematic review
Rhinology (PubMed 40202087), 2025
Choulakis et al.: 33 clinical studies of 11 herbal preparations to February 2024; BNO 1016 has significant evidence for acute rhinosinusitis.
-
Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review
Frontiers in Pediatrics (PubMed 40376625), 2025
Kamin et al.: open-label studies of the five-herb syrup (BNO 1012) in children, including Popovych 2020 with 292 children aged 6 to 11; possible adjunct, grade IIC; funded by Dr. Willmar Schwabe, maker of EPs 7630.
-
Sinupret extract: Fachinformation (summary of product characteristics)
Bionorica SE, via Rote Liste Service (fachinfo.de), 2024
German label, March 2024: 160 mg dry extract (3–6:1), 1:3:3:3:3; ages 12 and up; 3 × 1 tablet for 7–14 days; ulcer contraindication; pregnancy and breastfeeding; side effects; ARhiSi-2 results (386 patients, MSS 2.38 versus 3.41); authorized 2012.
-
Sinupret extract, Dragées: Fachinformation
Swissmedic product information (AIPS), Biomed AG / Bionorica SE, 2021
Names Rumex crispus herb among the five herbs; adults only; red-flag symptoms; no interaction or human pharmacodynamic studies; animal and laboratory findings for Sinupret drops.
-
Public Assessment Report: Sinupret, coated tablet; Sinupret Forte, coated tablet
Läkemedelsverket (Swedish Medical Products Agency), 2012
Powdered-herb tablets: 6 and 18 mg per tablet, forte double; six permitted Rumex species; well-established use approval based on the 1994 add-on trial in 160 men; mechanism unclear; isolated serious skin reactions.
-
Sinupret forte: Gebrauchsinformation (package leaflet)
Bionorica SE, 2026
Powdered herbs per tablet: gentian root 12 mg; vervain, garden sorrel, elder flower, and cowslip flower with calyx 36 mg each; ages 12 and up; red-flag symptoms; no known or studied interactions.
-
Sinupret Saft: Fachinformation (summary of product characteristics)
Bionorica SE, via Rote Liste Service (fachinfo.de), 2023
Syrup from age 2; doses 2.1, 3.5, and 7 ml three times daily; 450 mg alcohol per 7 ml; retrospective analysis of 762 pregnancies; warning signs of severe rhinosinusitis.
-
Sinupret Adult Strength, 50 tablets: ingredients
Bionorica USA, 2026
US product: primula flower, sorrel (six Rumex species), elder flower, and vervain 30 mg each and gentian root 10 mg per tablet; described by the company as an herbal supplement.
-
Assessment report on Primula veris L. and/or Primula elatior (L.) Hill, flos
European Medicines Agency (EMA/HMPC/136583/2012), 2012
No trials of primula flower alone; data on the five-herb combination excluded because the flower’s contribution cannot be estimated; allergic reports with the combination; allergenic quinones.
-
Company history
Bionorica SE, 2021
Founded by Josef Popp in Nuremberg in 1933; Sinupret and Sinupret forte newly registered in Germany in 1997; Sinupret extract launched in autumn 2012 and in ten more countries in 2014.